Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 77

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 77
---
:Recurring$2,787 $2,400 $4,297 $9,484 Nonrecurring450 1,115 490 2,055 Total$3,237 $3,515 $4,787 $11,539 (a) The Company defines North America as the United States and Canada.(b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets.(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand).  The Company defines developed markets as all markets of the world that are not high-growth markets.The Company’s products and services primarily consist of life sciences research, biopharmaceutical drug production and medical diagnostic products and services.  The Company sells equipment to customers as well as consumables, software and services, some of which customers purchase on a recurring basis.  Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle.  Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing and filters used in filtration, separation and purification processes.  Additionally, some of the Company’s consumables are used on a standalone basis, such as custom nucleic acids, genomics solutions, antibodies and immunoassays.  The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis.  Recurring revenue includes revenue from consumables (both used with Company equipment and used on a standalone basis), services and operating-type leases (“OTLs”).  Nonrecurring revenue includes sales of equipment and sales-type leases (“STLs”).  OTLs and STLs are included in the above revenue amounts.  For the three-month periods ended June 27, 2025 and June 28, 2024, lease revenue was $117 million and $95 million, respectively.  For the six-month periods ended June 27, 2025 and June 28, 2024, lease revenue was $231 million